LATAM Cargo has announced that its pharmaceutical product transportation between Europe and Brazil grew approximately 150% from January to July 2026 compared to the same period last year.
The airline said the surge was mainly driven by an increase in the transport of GLP-1-based medications, a class used in treatments for type 2 diabetes.
In the first seven months of the year, GLP-1-based medications accounted for approximately 15% of the total volume transported by the company between Europe and Brazil.
Considering all cargo types, LATAM Cargo moved nearly 32,000 tonnes between the two markets during this period - a 27% increase compared to the first seven months of 2025.
Around 75% of this volume consisted of general and consolidated cargo, including automation products, mining machinery, textiles, and commodities.
Jorge Carretero, cargo sales manager Europe at LATAM Airlines Group, said: "The growth in pharmaceutical transport demonstrates how demand for specialised logistics solutions is gaining prominence between Europe and Brazil.
"Our priority is to support this evolution through a safe, efficient operation equipped for the specific requirements of each cargo type.
"At the same time, the 27% growth in total volume reinforces the importance of connectivity between both markets and our network's capacity to serve diverse economic sectors."
